Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration.
The effects of a combination of intranasal (i.n.) and subcutaneous (s.c.) administration of inactivated influenza vaccine for priming and boosting on the cross-protection against antigenically drifted virus challenge were examined in Balb/c mice. Mice were primed through the i.n. or s.c. route with a CTB*-A/Kumamoto/37/79 (H1N1) combined vaccine (CTB*: cholera toxin B subunit supplemented with 0.2% of the holotoxin) and boosted through the i.n. or s.c. route with another drift virus vaccine, A/Bangkok/10/83 (H1N1), 4 weeks later. Two weeks after boosting, the mice were challenged with a third drift virus, A/Yamagata/120/86 (H1N1). The combination of i.n. priming and i.n. boosting afforded the highest cross-protection, while combinations of s.c. priming and i.n. or s.c. boosting afforded little cross-protection. In parallel with the protective activity, anti-A/Yamagata haemagglutinin-reactive IgA and IgG antibodies were detected in nasal and bronchoalveolar wash specimens. These results suggest that cross-protection against a variant virus challenge is most favourably provided by i.n. priming with the CTB* combined vaccine and i.n. boosting with the vaccine, which optimally induces cross-protective IgA and IgG antibodies.
Asanuma
H
H
Department of Pathology, National Institute of Health, Tokyo, Japan.
Koide
F
F
Suzuki
Y
Y
Nagamine
T
T
Aizawa
C
C
Kurata
T
T
Tamura
S
S
D000281:Administration, Intranasal; D000818:Animals; D007252:Influenza Vaccines / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D051379:Mice; D008807:Mice, Inbred BALB C; D009976:Orthomyxoviridae Infections / Q000517:prevention & control*
D007252:Influenza Vaccines